Concord Biotech informs about updates
Concord Biotech has informed regarding the successful completion of the European Union Good Manufacturing Practice (EU GMP) inspection at Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 14’ 2025 to July 18’ 2025. This achievement underscores its unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance across all aspects of its operations. It reflects its dedication to excellence and its continued focus on meeting the rigorous requirements of global regulatory authorities.
The above information is a part of company’s filings submitted to BSE.
